COVID-19-related dynamic coagulation disturbances and anticoagulation strategies using conventional D-dimer and point-of-care Sonoclot tests: a prospective cohort study
Madhumita Premkumar,Sekar Loganathan,Kamal Kajal,Amarjyoti Hazarika,Shiv Soni,Goverdhan Dutt Puri,Inderpaul Singh Sehgal,Vikas Suri,Pankaj Malhotra,Virendra Singh,Ajay Duseja,Ashish Bhalla,Jasmina Ahluwalia,Narender Kumar,Kushal Kekan,Sant Ram,Karan Singla,Varun Mahajan,Narayana Yaddanapudi,Premkumar,M.,Loganathan,S.,Kajal,K.,Hazarika,A.,Soni,S.,Puri,G. D.,Sehgal,I. S.,Suri,V.,Malhotra,P.,Singh,V.,Duseja,A.,Bhalla,A.,Ahluwalia,J.,Kumar,N.,Kekan,K.,Ram,S.,Singla,K.,Mahajan,V.,Yaddanapudi,N.
DOI: https://doi.org/10.1136/bmjopen-2021-051971
IF: 3.006
2022-05-02
BMJ Open
Abstract:Objectives Coagulation changes associated with COVID-19 suggest the presence of a hypercoagulable state with pulmonary microthrombosis and thromboembolic complications. We assessed the dynamic association of COVID-19-related coagulation abnormalities with respiratory failure and mortality. Design Single-centre, prospective cohort study with descriptive analysis and logistic regression. Setting Tertiary care hospital, North India. Participants Patients with COVID-19 pneumonia requiring intensive care unit (ICU) admission between August 2020 and November 2020. Primary and secondary outcome measures We compared the coagulation abnormalities using standard coagulation tests like prothrombin time, D-dimer, platelet count, etc and point-of-care global coagulation test, Sonoclot (glass beaded(gb) and heparinase-treated(h)). Incidence of thromboembolic or bleeding events and presence of endogenous heparinoids were assessed. Cox proportional Hazards test was used to assess the predictors of 28-day mortality. Measurement All patients underwent Sonoclot (glass beaded) test at admission apart from the routine investigations. In patients at risk of thromboembolic or bleeding phenomena, paired tests were performed at day 1 and 3 with Sonoclot. Activated clotting time (ACT) 75 units were used as the cut-off for hypercoagulable state. Presence of heparin-like effect (HLE) was defined by a correction of ACT ≥40 s in h-Sonoclot. Results Of 215 patients admitted to ICU, we included 74 treatment naive subjects. A procoagulant profile was seen in 45.5% (n=5), 32.4% (n=11) and 20.7% (n=6) in low-flow, high-flow and invasive ventilation groups. Paired Sonoclot assays in a subgroup of 33 patients demonstrated the presence of HLE in 17 (51.5%) and 20 (62.5%) at day 1 and 3, respectively. HLE (day 1) was noted in 59% of those who bled during the disease course. Mortality was observed only in the invasive ventilation group (16, 55.2%) with overall mortality of 21.6%. HLE predicted the need for mechanical ventilation (HR 1.2 CI 1.04 to 1.4 p=0.00). On multivariate analysis, the presence of HLE (HR 1.01; CI 1.006 to 1.030; p=0.025), increased C reactive protein (HR 1.040; CI 1.020 to 1.090; p=0.014), decreased platelet function (HR 0.901; CI 0.702 to 1.100 p=0.045) predicted mortality at 28days. Conclusion HLE contributed to hypocoagulable effect and associated with the need for invasive ventilation and mortality in patients with severe COVID-19 pneumonia. Trial registration NCT04668404; ClinicalTrials.gov.in. Available from https://clinicaltrials.gov/ct2/show/NCT04668404.
medicine, general & internal